Marathon Capital Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $505K | Sell |
8,324
-240
| -3% | -$14K | 0.11% | 102 |
|
|
2025
Q4 | $462K | Hold |
8,564
| – | – | 0.1% | 113 |
|
|
2025
Q3 | $386K | Buy |
8,564
+755
| +10% | +$35.3K | 0.09% | 112 |
|
|
2025
Q2 | $361K | Sell |
7,809
-955
| -11% | -$46.9K | 0.09% | 114 |
|
|
2025
Q1 | $535K | Sell |
8,764
-44
| -0.5% | -$2.56K | 0.14% | 88 |
|
|
2024
Q4 | $498K | Buy |
8,808
+263
| +3% | +$14.7K | 0.12% | 94 |
|
|
2024
Q3 | $442K | Sell |
8,545
-175
| -2% | -$8.21K | 0.11% | 100 |
|
|
2024
Q2 | $362K | Sell |
8,720
-106,160
| -92% | -$4.75M | 0.09% | 105 |
|
|
2024
Q1 | $6.23M | Buy |
114,880
+746
| +0.7% | +$38K | 1.49% | 17 |
|
|
2023
Q4 | $5.86M | Sell |
114,134
-6,593
| -5% | -$346K | 1.47% | 18 |
|
|
2023
Q3 | $7.01M | Buy |
120,727
+1,185
| +1% | +$72.6K | 1.76% | 12 |
|
|
2023
Q2 | $7.64M | Sell |
119,542
-943
| -0.8% | -$63.2K | 1.89% | 8 |
|
|
2023
Q1 | $8.35M | Buy |
120,485
+19,228
| +19% | +$1.36M | 2.05% | 5 |
|
|
2022
Q4 | $7.29M | Sell |
101,257
-29
| -0% | -$2.19K | 2.01% | 7 |
|
|
2022
Q3 | $7.2M | Buy |
101,286
+27,033
| +36% | +$1.96M | 2.06% | 6 |
|
|
2022
Q2 | $5.72M | Sell |
74,253
-17,110
| -19% | -$1.3M | 1.85% | 6 |
|
|
2022
Q1 | $6.67M | Sell |
91,363
-105
| -0.1% | -$7.05K | 1.92% | 6 |
|
|
2021
Q4 | $5.7M | Sell |
91,468
-502
| -0.5% | -$29.4K | 1.34% | 9 |
|
|
2021
Q3 | $5.44M | Buy |
91,970
+15,751
| +21% | +$1.04M | 1.24% | 8 |
|
|
2021
Q2 | $5.09M | Sell |
76,219
-811
| -1% | -$52.9K | 1.18% | 12 |
|
|
2021
Q1 | $4.86M | Buy |
77,030
+10,238
| +15% | +$637K | 1.28% | 11 |
|
|
2020
Q4 | $4.14M | Buy |
66,792
+3,754
| +6% | +$231K | 1.22% | 13 |
|
|
2020
Q3 | $3.8M | Sell |
63,038
-2,154
| -3% | -$130K | 1.38% | 10 |
|
|
2020
Q2 | $3.83M | Sell |
65,192
-46
| -0.1% | -$2.75K | 1.47% | 9 |
|
|
2020
Q1 | $3.64M | Buy |
65,238
+13,204
| +25% | +$807K | 1.67% | 5 |
|
|
2019
Q4 | $3.34M | Buy |
52,034
+31,057
| +148% | +$1.78M | 1.14% | 11 |
|
|
2019
Q3 | $1.06M | Buy |
20,977
+840
| +4% | +$39.5K | 0.43% | 39 |
|
|
2019
Q2 | $913K | Buy |
20,137
+6,230
| +45% | +$290K | 0.37% | 42 |
|
|
2019
Q1 | $663K | Buy |
13,907
+9,183
| +194% | +$457K | 0.3% | 51 |
|
|
2018
Q4 | $245K | Sell |
4,724
-500
| -10% | -$26.9K | 0.12% | 80 |
|
|
2018
Q3 | $324K | Sell |
5,224
-600
| -10% | -$35.6K | 0.13% | 77 |
|
|
2018
Q2 | $322K | Sell |
5,824
-25
| -0.4% | -$1.35K | 0.12% | 76 |
|
|
2018
Q1 | $369K | Sell |
5,849
-238
| -4% | -$15.3K | 0.14% | 64 |
|
|
2017
Q4 | $373K | Sell |
6,087
-25
| -0.4% | -$1.56K | 0.15% | 63 |
|
|
2017
Q3 | $390K | Hold |
6,112
| – | – | 0.16% | 52 |
|
|
2017
Q2 | $341K | Sell |
6,112
-150
| -2% | -$8.16K | 0.16% | 54 |
|
|
2017
Q1 | $341K | Hold |
6,262
| – | – | 0.17% | 55 |
|
|
2016
Q4 | $365K | Hold |
6,262
| – | – | 0.17% | 51 |
|
|
2016
Q3 | $338K | Hold |
6,262
| – | – | 0.17% | 55 |
|
|
2016
Q2 | $461K | Sell |
6,262
-107
| -2% | -$7.56K | 0.24% | 46 |
|
|
2016
Q1 | $407K | Hold |
6,369
| – | – | 0.21% | 48 |
|
|
2015
Q4 | $438K | Buy |
6,369
+300
| +5% | +$19.8K | 0.23% | 47 |
|
|
2015
Q3 | $359K | Sell |
6,069
-75
| -1% | -$4.76K | 0.18% | 54 |
|
|
2015
Q2 | $409K | Buy |
6,144
+71
| +1% | +$4.68K | 0.19% | 50 |
|
|
2015
Q1 | $392K | Buy |
6,073
+1,050
| +21% | +$65.7K | 0.17% | 52 |
|
|
2014
Q4 | $297K | Sell |
5,023
-1,500
| -23% | -$84.6K | 0.27% | 52 |
|
|
2014
Q3 | $334K | Sell |
6,523
-1,200
| -16% | -$59.9K | 0.3% | 53 |
|
|
2014
Q2 | $375K | Hold |
7,723
| – | – | 0.3% | 49 |
|
|
2014
Q1 | $401K | Hold |
7,723
| – | – | 0.3% | 46 |
|
|
2013
Q4 | $410K | Hold |
7,723
| – | – | 0.3% | 46 |
|
|
2013
Q3 | $357K | Hold |
7,723
| – | – | 0.31% | 49 |
|
|
2013
Q2 | $345K | Buy |
+7,723
| New | +$335K | 0.29% | 50 |
|
Other funds holding BMY
VCM
VPM
Marathon Capital Management's BMY Position: Q1 2026 in Review
Marathon Capital Management reduced its Bristol-Myers Squibb (BMY) stake by 2.8% in Q1 2026, selling an estimated $14K and leaving 8,324 shares worth $505K. The position accounts for 0.11% of the portfolio, ranked #102.
Marathon Capital Management first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $8.35M in Q1 2023. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Marathon Capital Management held 8,324 shares of Bristol-Myers Squibb worth $505K as of Q1 2026.
- Marathon Capital Management sold 240 Bristol-Myers Squibb shares in Q1 2026, an estimated $14K.
- Bristol-Myers Squibb made up 0.11% of Marathon Capital Management's portfolio in Q1 2026, its #102 holding.
- Marathon Capital Management first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
- Marathon Capital Management's Bristol-Myers Squibb position peaked at $8.35M in Q1 2023.
- 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Marathon Capital Management's 13F filing for Q1 2026, filed 14 May 2026.